サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1433445

E型肝炎診断検査の世界市場：2023-2030年

Global Hepatitis E Diagnostic Tests Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 240 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
E型肝炎診断検査の世界市場：2023-2030年
出版日: 2024年01月11日
発行: Orion Market Research
ページ情報: 英文 240 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のe型肝炎診断検査市場は予測期間（2024-2031年）にCAGR 7.40％で成長すると予測されます。市場の成長は、世界の健康問題に対する需要に起因しています。公衆衛生の主要な懸念としてのE型肝炎の世界の流行と重要性は、この病気が公衆衛生に及ぼす影響を効果的に管理し最小化するための診断検査の継続的な成長と受容の動機となっています。2023年5月の国立衛生研究所（National Institute of Health（gov.））によると、E型肝炎はE型肝炎ウイルス（HEV）によって引き起こされる肝臓の炎症であり、一般的に汚染された水や加熱不十分な動物肉（特に豚肉）の摂取によって感染します。世界保健機関（WHO）によると、年間約2,000万件のHEV感染があり、330万人の有症状者と44,000人の死亡者を出しています。これはウイルス性肝炎による死亡者の3.3％を占める。一方、E型肝炎は世界的に流行しています。

セグメント別の展望

血清検査サブセグメントが世界のE型肝炎診断検査市場でかなりのシェアを占めると予測される

疾患タイプ別では、血清検査サブセグメントが世界のE型肝炎診断検査市場でかなりのシェアを占めると予想されます。このセグメントの成長は血清学的検査の進歩によるものです。酵素免疫測定（EIA）検査、特にIgMおよびIgG抗HEV抗体を同定できる受動的EIA技術のイントロダクションは、E型肝炎診断検査のための血清学的検査における技術的進歩を強調しています。IgM抗体とIgG抗体の区分は、現代あるいは過去の疾患の同定を助ける。MDPIによると、2021年1月、HEV感染の検出に用いられる血清学的検査には、酵素免疫測定法（EIA）検査が含まれます。間接EIA検査はIgMおよびIgG抗HEV抗体を検出することができます。IgM抗HEV抗体は最初に出現し、急性または最近の感染を示しますが、IgG抗HEV抗体は何年も持続し、最近または過去の感染を示唆します。しかし、これらの検査法の感度や特異性は様々であり、CMVやEBVなどの他のウイルスとの交差反応性の可能性もあります。 Wantai検査は、IgM検出に最も一般的に使用されている市販の ELISAテストであり、EIAテストの中でも感度と特異性が高いことで知られています

地域別展望

世界のE型肝炎診断検査市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、中南米）を含む地域別にさらに細分化されます。このうち、アジア太平洋地域は、ヘルスケア施設の増加、適用可能なメーカーの多さ、政府の関与と熟練したコミュニティの増加により、世界市場で突出したシェアを占めると予想されます。

北米地域は、世界のE型肝炎診断検査市場において大幅なCAGRで成長すると予想されています

すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予想されます。 同地域の成長は、地域全体での診断検査の開発によるものです。このような研究からの洞察は、より完全な診断像を提供し、疾患の動態の理解を助けるために、抗体やウイルスRNAなどのE型肝炎感染の多数のマーカーを同定できる診断検査の開発の動機となっています。 MDPIによると、2023年10月、エストニアで1002人のドナー血清の抗HEV IgG抗体とIgM抗体、およびウイルスRNAの有病率が分析されました。このうち48血清（4.8％）が抗HEV抗体陽性で、40血清（4％）が抗HEV IgG、15血清（1.5％）が抗HEV IgMでした。さらに7人のドナーは両クラスの抗体を同時に有していました。しかし、年齢とともに抗 HEV IgG キャリアの発生率が高くなる場合、統計分析では、感染リスク変数と抗 HEV 抗体の保有率の間に統計的に有意な関連性は確認されませんでした。

目次

第1章 レポート概要

  • 業界の現状分析と成長可能性の展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Abbott
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Becton, Dickinson, and Co.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • BIOMERIEUX
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • E型肝炎診断薬の世界市場：疾患タイプ別
    • 血清学検査
    • 分子検査
    • 免疫測定法
    • ポイントオブケア検査
  • E型肝炎診断検査の世界市場：技術別
    • 酵素結合免疫吸着測定法（ELISA）
    • 迅速診断試験（RDTs）
    • 次世代シーケンス（NGS）
    • 核酸増幅検査（NAAT）
  • E型肝炎診断検査の世界市場：エンドユーザー別
    • 病院および診療所
    • 診断研究所
    • 公衆衛生機関および研究機関

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Bio-Rad Laboratories, Inc.
  • Danaher Corp.
  • Diasorin S.p.A.,
  • EKF Diagnostics Holdings plc
  • ELITech Group
  • F. Hoffmann-La Roche Ltd
  • Grifols
  • Hologic, Inc.
  • InBios International, Inc.
  • Mast Group Ltd.
  • QIAGEN GmbH
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific Inc.
  • VWR International, LLC
図表

LIST OF TABLES

  • 1. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 2. GLOBAL SEROLOGY TESTS HYSTEROSCOPE HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 3. GLOBAL MOLECULAR TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 4. GLOBAL IMMUNOASSAYS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 5. GLOBAL POINT-OF-CARE TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 6. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 7. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 8. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN RAPID DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 9. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN NUCLEIC ACID AMPLIFICATION TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 10. GLOBAL OTHERS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 11. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 12. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 13. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR DIAGNOSTIC LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 14. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR PUBLIC HEALTH AGENCIES AND RESEARCH INSTITUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 15. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 16. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 17. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 18. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 19. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 20. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)
  • 21. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 22. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 23. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 24. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)
  • 25. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 26. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 27. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 28. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)
  • 29. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 30. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 31. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 32. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY DISEASE TYPE, 2023 VS 2031(%)
  • 2. GLOBAL SEROLOGY TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 3. GLOBAL MOLECULAR TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 4. GLOBAL IMMUNOASSAYS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 5. GLOBAL POINT-OF-CARE TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 6. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY TECHNOLOGY, 2023 VS 2031(%)
  • 7. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 8. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN RAPID DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 9. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN NEXT-GENERATION SEQUENCING TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 10. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN NUCLEIC ACID AMPLIFICATION TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 11. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY END USER, 2023 VS 2031(%)
  • 12. GLOBAL HEPATITIS E DIAGNOSTIC TESTS HOSPITALS AND CLINICS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 13. GLOBAL HEPATITIS E DIAGNOSTIC TESTS DIAGNOSTIC LABORATORIES MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 14. GLOBAL HEPATITIS E DIAGNOSTIC TESTS PUBLIC HEALTH AGENCIES AND RESEARCH INSTITUTIONS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 15. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 16. US HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 17. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 18. UK HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 19. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 20. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 21. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 22. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 23. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 24. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 25. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 26. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 27. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 29. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
目次
Product Code: OMR2028071

Global Hepatitis E Diagnostic Tests Market Size, Share & Trends Analysis Report by Disease Type (Serology Tests, Molecular Tests, Immunoassays, and Point-of-Care Tests), by Technology (Enzyme-Linked Immunosorbent Assay, Rapid Diagnostic Tests, Next-Generation Sequencing, and Nucleic Acid Amplification Tests) and by End User (Hospitals and Clinics, Diagnostic Laboratories, and Public Health Agencies and Research Institutions), Forecast Period (2024-2031)

The global hepatitis e diagnostic tests market is anticipated to grow at a CAGR of 7.40% during the forecast period (2024-2031). The market's growth is attributed to the demand for global health concern. The global prevalence and significance of Hepatitis E as a major public health concern motivate continued growth and acceptance of diagnostic tests to effectively manage and minimize the disease's impact on public health. According to the National Institute of Health (gov.) in May 2023, the hepatitis E is a liver inflammation caused by the hepatitis E virus (HEV), that is commonly transmitted through contaminated water or the consumption of undercooked animal meat, particularly pork. According to the World Health Organization (WHO), there are approximately 20 million HEV infections annually, resulting in 3.3 million symptomatic cases and 44,000 deaths. This accounts for 3.3% of viral hepatitis-related mortalities. While hepatitis E is prevalent globally.

Segmental Outlook

The global hepatitis E diagnostic tests market is segmented on the product type, animal type, application, and end user. Based on the product type, the market is sub-segmented into stationary multi-slice CT scanner, and portable CT scanner. Based on the animal type, the market is sub-segmented into companion animal, livestock animal, others. Based on the application, the market is sub-segmented into neurology, oncology, cardiology, nephrology, gastroenterology, and others. Furthermore, on the basis of end-user, the market is sub-segmented into veterinary clinics and hospitals, research institutes, and others. The enzyme-linked immunosorbent assay (ELISA) subcategory is expected to capture a significant portion of the market share within the technology segment. The growth can be attributed to the widespread adoption of the procedure to diagnose hepatitis in hospitals.

The Serology Tests Sub-Segment is Anticipated to Hold a Considerable Share of the global Hepatitis E Diagnostic Tests Market

Among the disease type, the serology tests sub-segment is expected to hold a considerable share of the global Hepatitis E Diagnostic Tests market. The segmental growth is attributed to the advancement in serological testing. The introduction of Enzyme Immunoassay (EIA) testing, specifically passive EIA techniques capable of identifying IgM and IgG anti-HEV antibodies, emphasizes technological advances in serology tests for Hepatitis E diagnosis. The division between IgM and IgG antibodies aids in the identification of modern or previous diseases. According to the MDPI, in January 2021, serological tests used to detect HEV infection include enzyme immunoassay (EIA) tests. Indirect EIA assays are capable of detecting IgM and IgG anti-HEV antibodies. IgM anti-HEV antibodies are the first to appear, indicating an acute or recent infection, while IgG anti-HEV antibodies persist for years, suggesting a recent or past infection. However, the sensitivity and specificity of these assays can vary, and there is a potential for cross-reactivity with other viruses such as CMV and EBV. The Wantai test is the most commonly used commercial ELISA test for IgM detection, known for its high sensitivity and specificity among EIA tests.

Regional Outlook

The global hepatitis E diagnostic tests market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the growing healthcare facilities, a significant amount of applicable manufacturer and rise in government involvement and proficient communities.

The North America Region is Expected to Grow at a Significant CAGR in the global Hepatitis E Diagnostic Tests Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the diagnostic test development across the region. Insights from such studies motivate the development of diagnostic tests capable of identifying numerous markers of Hepatitis E infection, such as antibodies and viral RNA, in order to provide a more complete diagnostic picture and aid in understanding disease dynamics. According to the MDPI, in October 2023, the prevalence of anti-HEV IgG and IgM antibodies, as well as viral RNA, was analyzed in 1002 donor sera in Estonia. Out of these, 48 sera (4.8%) tested positive for anti-HEV antibodies, with 40 (4%) containing anti-HEV IgG and 15 (1.5%) containing anti-HEV IgM. Additionally, 7 donors had antibodies of both classes simultaneously. However, no HEV RNA was detected in any of the blood serum samples. However for a higher incidence of anti-HEV IgG carriers with age, statistical analysis identified no statistically significant associations between infection risk variables and the prevalence of anti-HEV antibodies.

Market Players Outlook

The major companies serving the hepatitis E diagnostic tests market includes Bio-Rad Laboratories, Inc., Danaher Corp., Diasorin S.p.A., EKF Diagnostics Holdings plc, ELITech Group, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2022,Gilead Sciences, Inc. collaborated with Brigham and Women's Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. This multi-year program comprises a staged approach to addressing barriers to viral hepatitis diagnosis and management in basic healthcare authorities in Vietnam and the Philippines, two countries with significant hepatitis B and C prevalence.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global hepatitis E diagnostic tests market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abbott
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Becton, Dickinson, and Co.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. BIOMERIEUX
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Hepatitis E Diagnostic Tests Market by Disease Type
    • 4.1.1. Serology Tests
    • 4.1.2. Molecular Tests
    • 4.1.3. Immunoassays
    • 4.1.4. Point-of-Care Tests
  • 4.2. Global Hepatitis E Diagnostic Tests Market by Technology
    • 4.2.1. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 4.2.2. Rapid Diagnostic Tests (RDTs)
    • 4.2.3. Next-Generation Sequencing (NGS)
    • 4.2.4. Nucleic Acid Amplification Tests (NAAT)
  • 4.3. Global Hepatitis E Diagnostic Tests Market by End-User
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Diagnostic Laboratories
    • 4.3.3. Public Health Agencies and Research Institutions

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bio-Rad Laboratories, Inc.
  • 6.2. Danaher Corp.
  • 6.3. Diasorin S.p.A.,
  • 6.4. EKF Diagnostics Holdings plc
  • 6.5. ELITech Group
  • 6.6. F. Hoffmann-La Roche Ltd
  • 6.7. Grifols
  • 6.8. Hologic, Inc.
  • 6.9. InBios International, Inc.
  • 6.10. Mast Group Ltd.
  • 6.11. QIAGEN GmbH
  • 6.12. Siemens Healthineers
  • 6.13. Sysmex
  • 6.14. Thermo Fisher Scientific Inc.
  • 6.15. VWR International, LLC